Mohanad Mahmoud Elfishawi, MBCHB

Mohanad Elfishawi practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Mohanad Elfishawi's NPI, 1396266052, was assigned on July 3, 2017. Mohanad Elfishawi holds Minnesota license 66912.

Mohanad Elfishawi's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Mohanad Elfishawi's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Mohanad Elfishawi is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Mohanad Elfishawi to 3 more hospitals, 3 group practices and clinics, 2 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mohanad Elfishawi practices, 9 sites in all. Vendor and product names are available with a free account.

Rheumatology is Mohanad Elfishawi's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Mohanad Elfishawi is licensed in Minnesota.

CMS data shows 226 Medicare services from Mohanad Elfishawi across 6 procedure codes in 2024, for 87 Medicare patients. Medicare paid $15,409 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 87 Medicare patients who saw Mohanad Elfishawi in 2024. The largest group is under 65, with 34 patients. 75% of them have arthritis, and 74% have high blood pressure. 36% are also on Medicaid. Their average risk score is 3.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mohanad Elfishawi's median patient age at 61, with 67% women.

In 2024, Mohanad Elfishawi wrote 690 Medicare Part D claims for 127 patients. 77% of them were for generic drugs. CMS names the drug for 550 of them, across 15 drugs with 11 or more claims each, at $521,777 in total drug cost. In 2023, CMS named 195 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Mohanad Elfishawi for performance year 2024, reported as part of a group. Mohanad Elfishawi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mohanad Elfishawi as offering telehealth.

Dmand AI links 22 papers to Mohanad Elfishawi, published from 2017 to 2024. 2018 was the busiest year, with 4. The most frequent topics are Giant Cell Arteritis, Aorta and Comorbidity. Mohanad Elfishawi has published most often in J Rheumatol. Mohanad Elfishawi's most frequent co-authors are Kenneth J. Warrington, MD, Tim Bongartz, MD and Clement J. Michet, MD.

CMS Open Payments shows 2 general payments to Mohanad Elfishawi from 1 drug or device company in 2021. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $50.